Efficacy and safety of bariatric surgery for craniopharyngioma-related hypothalamic obesity: a matched case–control study with 2 years of follow-up
Background: Hypothalamic obesity is a devastating consequence of craniopharyngioma. Bariatric surgery could be a promising therapeutic option. However, its efficacy and safety in patients with craniopharyngioma-related hypothalamic obesity remain largely unknown. Objectives: We investigated the effi...
Saved in:
Published in | International Journal of Obesity Vol. 41; no. 2; pp. 210 - 216 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
London
Nature Publishing Group UK
01.02.2017
Nature Publishing Group |
Subjects | |
Online Access | Get full text |
ISSN | 0307-0565 1476-5497 1476-5497 |
DOI | 10.1038/ijo.2016.195 |
Cover
Summary: | Background:
Hypothalamic obesity is a devastating consequence of craniopharyngioma. Bariatric surgery could be a promising therapeutic option. However, its efficacy and safety in patients with craniopharyngioma-related hypothalamic obesity remain largely unknown.
Objectives:
We investigated the efficacy of bariatric surgery for inducing weight loss in patients with craniopharyngioma-related hypothalamic obesity. In addition, we studied the safety of bariatric surgery regarding its effects on hormone replacement therapy for pituitary insufficiency.
Methods:
In this retrospective matched case–control study, we compared weight loss after bariatric surgery (that is, Roux-en-Y gastric bypass and sleeve gastrectomy) between eight patients with craniopharyngioma-related hypothalamic obesity and 75 controls with ‘common’ obesity during 2 years of follow-up. We validated our results at 1 year of follow-up in a meta-analysis. In addition, we studied alterations in hormone replacement therapy after bariatric surgery in patients with craniopharyngioma.
Results:
Mean weight loss after bariatric surgery was 19% vs 25% (difference −6%, 95% confidence of interval (CI) −14.1 to 4.6;
P
=0.091) at 2 years of follow-up in patients with craniopharyngioma-related hypothalamic obesity compared with control subjects with ‘common’ obesity. Mean weight loss was 25% vs 29% (difference −4%, 95% CI −11.6 to 8.1;
P
=0.419) after Roux-en-Y gastric bypass and 10% vs 20% (difference −10%, 95% CI −14.1 to −6.2;
P
=0.003) after sleeve gastrectomy at 2 years of follow-up in patients with craniopharyngioma-related hypothalamic obesity vs control subjects with ‘common’ obesity. Our meta-analysis demonstrated significant weight loss 1 year after Roux-en-Y gastric bypass, but not after sleeve gastrectomy. Seven patients with craniopharyngioma suffered from pituitary insufficiency; three of them required minor adjustments in hormone replacement therapy after bariatric surgery.
Conclusions:
Weight loss after Roux-en-Y gastric bypass, but not sleeve gastrectomy, was comparable between patients with craniopharyngioma-related hypothalamic obesity and control subjects with ‘common’ obesity at 2 years of follow-up. Bariatric surgery seems safe regarding its effects on hormone replacement therapy. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 |
ISSN: | 0307-0565 1476-5497 1476-5497 |
DOI: | 10.1038/ijo.2016.195 |